Emergency Medicine Cardiac Research and Education Group


CRUSADE
CRUSADE Quality Improvement Initiative

Launched in 2001, CRUSADE is a national quality improvement initiative, designed to increase the practice of evidence-based medicine for patients diagnosed with non-ST segment elevation acute coronary syndromes (NSTE ACS) (i.e., unstable angina or NSTE myocardial infarction).

Through a continuous cycle of data collection, performance feedback and quality improvement interventions, over 500 participating sites in the US are consistently improving the standard of care for patients with NSTE ACS. Because of the dedication of the participating hospitals to this mission, over 200,000 cases have been submitted to the CRUSADE database. For more information visit the CRUSADE website.

In 2007, a milestone occurred. Duke Clinical Research Institute and its CRUSADE leadership joined forces with the American College of Cardiology Foundation's National Cardiovascular Data Registry (NCDR™) to launch a new initiative to improve the safety and outcomes for patients with ACS through the development of NCDR-ACTION™. This initiative will combine the data collection and quality reporting features of two leading national ACS registries to create the largest and most comprehensive national cardiovascular patient database ever developed. For more information visit the NCDR-ACTION Registry™ visit the website or call 800-257-4737 for more information.




Comparison of the Predictive Value of Four Different Risk Scores for Outcomes of Patients With ST-Elevation Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention



Am J Cardiol 2008;102:6-11 View citation

Accurate risk stratification has an important role in the management of patients with acute coronary syndromes. Even in patients with ST-elevation acute myocardial infarction (STEMI), for whom early therapeutic options are well defined, risk stratification has an impact on early and late therapeutic decision making. We aimed to compare the prognostic value of 4 risk scores used to evaluate patients with STEMI. We conducted a prospective registry of all patients treated with primary percutaneous coronary intervention for STEMI from January 2001 to June 2006. Excluded were patients with cardiogenic shock. A total of 855 consecutive patients were included in the analysis (age 60.5 ± 13 years, 19% women, 28% with diabetes, and 48% with anterior wall myocardial infarction). For each patient, the Thrombolysis In Myocardial Infarction (TIMI), Controlled Abciximab and Device Investigation to Lower Late Angioplasty complications (CADILLAC), Primary Angioplasty in Myocardial Infarction (PAMI), and Global Registry for Acute Coronary Events (GRACE) risk scores were calculated using specific clinical variables and angiographic characteristics. Thirty-day and 1-year clinical outcomes were assessed. The predictive accuracy of the 4 risk scores was evaluated using the area under the curve or C statistic method. The CADILLAC, TIMI, and PAMI risk scores all had relatively high predictive accuracy for 30-day and 1-year mortality (C statistic range 0.72 to 0.82), with slight superiority of the CADILLAC score. These 3 risk scores also performed well for prediction of reinfarction at 30 days (C statistic range 0.6 to 0.7). The GRACE score did not perform as well and had low predictive accuracy for mortality (C statistic 0.47). In conclusion, risk stratification of patients with STEMI undergoing primary percutaneous coronary intervention using the CADILLAC, TIMI, or PAMI risk scores provide important prognostic information and enables accurate identification of high-risk patients.




General navigation: Home | Member roster | Consultation | Our history | Contact
News & Events: Literature news archives | EM and related events
Education: Symposium monographs | CME monographs | Articles & Print | Multimedia
Publications: Member publications | Monographs

Legal information

EMCREG™ - International
Department of Emergency Medicine
University of Cincinnati College of Medicine
ML 0769, Room 6107
231 Albert Sabin Way
Cincinnati, Ohio 45267-0769

Fell free to contact us toll-free at 1-866-4EMCREG (436-2734)



Advanced Search

28 January 2010
Study results show that the TIMI risk score predicts outcomes in in emergency department with suspected ACS.
28 January 2010
Serial measurement of NT-proBNP predicts new-onset heart failure and cardiovascular mortality in elderly.
15 January 2010
Individual risk profiling of ACS patients could optimize therapeutic treatment choices.
15 January 2010
Results of the PLATO trial show that the reversible P2Y12 inhibitor ticagrelor reduces death and cardiovascular events compared with clopidogrel therapy in ACS patients.
5 January 2010
Study shows that high sensitive cardiac troponin I level is a useful prognostic marker of mortality in chronic heart failure patients.
23 December 2009
The largest and most comprehensive meta-analysis ever concludes that CRP is unlikely to be a causal factor for cardiovascular disease.
16 December 2009
Research shows that a substantial number of STEMI patients still receive fibrinolytic therapy at PCI capable centers.
11 December 2009
Denmark researchers report in Lancet that relative risk for hospitalization for bleeding increased with all drug combinations and with each additional drug used.
3 December 2009
Researchers report that prehospital triage significantly reduces treatment delay and improves outcomes in STEMI patients who undergo PCI.
30 November 2009
Researchers report that the to reperfusion, beginning with symptom onset time, determines the extent of reversible myocardial injury in STEMI patients undergoing PCI.
19 November 2009
Data presented at the AHA 2009 Scientific Sessions shows that dabigatran when added to dual anti-platelet therapy results in a “low and acceptable bleeding rate” in AMI patients.
19 November 2009
A must-read update for the management of acute coronary syndrome.
19 November 2009
Data presented at the AHA 2009 Scientific Sessions indicates that CT angiography in the emergency room can successfully triage at-risk chest-pain patients faster and cheaper than standard of care testing.
19 November 2009
Recent meta-analysis reveals that high-risk STEMI patients given adjunctive glycoprotein (GP) IIb/IIIa inhibitor therapy and undergo primary angioplasty have a reduced risk for death.
NEWS ARCHIVES:
©Copyright EMCREG-International™. All rights reserved